Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025Neuro-OncologyOpen Access

Ctni-16. Patient Backgrounds Associated With the Prolonged Effectiveness of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma: Results From the Rosetta Study

View Full Paper
Ask AI
Bookmark
Share

Authors

FYFumiyuki YamasakiKMKazuhiko MishimaMNManabu Natsumeda

Discussion

Loading...

Member takes

Overview

Cohort analysis reveals Karnofsky Performance Status and timing linked to prolonged progression-free survival in r/rPCNSL.

Key Points

  • To analyze patient characteristics that influence the prolonged effectiveness of tirabrutinib in r/rPCNSL patients.
  • Cohort analysis of 137 patients with r/rPCNSL treated with tirabrutinib from November 2020 to April 2022
  • Assessment of real-world progression-free survival based on various patient characteristics
  • Comparison of rwPFS in relation to prior treatments and Karnofsky Performance Status scores.
  • Patients with one prior treatment had longer rwPFS (16.3 months) vs those with ≥2 prior treatments (8.2 months)
  • Patients with a KPS score of 80–100 had similar rwPFS (11.0 months) to those with a score of 50–70 (10.7 months)
  • Median rwPFS was longer with an interval of ≥1 year from previous treatment (15.6 months) compared to <1 year (11.0 months).

Cite This Study

Yamasaki et al. (2025) studied this question.

synapsesocial.com/papers/69254362c0ce034ddc3581afhttps://doi.org/10.1093/neuonc/noaf201.0513
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P17.14.B A RETROSPECTIVE STUDY OF THE BTK-INHIBITOR TIRABRUTINIB FOR THE TREATMENT OF RECURRENT/REFRACTORY PRIMARY CNS LYMPHOMA2025
  2. 2DDDR-36. Tirabrutinib Therapy for Refractory or Relapsed Primary Central Nervous System Lymphoma: A Retrospective Analysis of 13 Cases2025
  3. 3Trial in progress: A phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed/Refractory primary central nervous system lymphoma2025
  4. 4Bruton's tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed/refractory primary diffuse large B-cell lymphoma of central nervous system.2024
  5. 5Post-marketing surveillance of tirabrutinib for Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma in Japan2026